These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 5468701)

  • 1. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
    Chopra IJ; Solomon DH; Limberg NP
    J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
    [No Abstract]   [Full Text] [Related]  

  • 2. [Relation between Basedow's disease and Hashimoto thyroiditis].
    Földes J; Takó J; Bános C; Gesztesi E; Juhász J
    Endokrinologie; 1971 Apr; 57(3):329-37. PubMed ID: 5108742
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
    Hardisty CA; Hanford L; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum immunoglobulin levels in thyroid disease.
    Glynne A; Thomson JA
    Clin Exp Immunol; 1972 Sep; 12(1):71-8. PubMed ID: 4628405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
    Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
    J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Human thyroid stimulator (HTS) in thyroid diseases].
    Hu ZY
    Zhonghua Nei Ke Za Zhi; 1984 Aug; 23(8):480-3, 525. PubMed ID: 6548953
    [No Abstract]   [Full Text] [Related]  

  • 7. Measurements by competitive binding radioassay of serum anti-microsomal and anti-thyroglobulin antibodies in Graves' disease and other thyroid disorders.
    Mori T; Kriss JP
    J Clin Endocrinol Metab; 1971 Oct; 33(4):688-98. PubMed ID: 5109861
    [No Abstract]   [Full Text] [Related]  

  • 8. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
    Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
    J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration of long-acting thyroid stimulator (LATS) by subfractionation of gamma G globulin from Graves' disease serum.
    Miyai K; Werner SC
    J Clin Endocrinol Metab; 1966 May; 26(5):504-12. PubMed ID: 5952570
    [No Abstract]   [Full Text] [Related]  

  • 10. The assay of Graves' immunoglobulins: a comparison of different methods.
    Hardisty CA; Kendall-Taylor P; Atkinson S; Humphries H; Munro DS
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):637-44. PubMed ID: 6136348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do thyroid-stimulating immunoglobulins cause non-toxic and toxic multinodular goitre?
    Brown RS; Jackson IM; Pohl SL; Reichlin S
    Lancet; 1978 Apr; 1(8070):904-6. PubMed ID: 76846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin levels and long-acting thyroid stimulator (LATS) in hyperthyroidism. A preliminary study.
    Yamakido M; Yokoyama M; Noguchi S
    Hawaii Med J; 1969; 29(2):118-9. PubMed ID: 5361480
    [No Abstract]   [Full Text] [Related]  

  • 13. Demonstration of the production of the long acting thyroid stimulator (LATS) by peripheral lymphocytes cultured in vitro.
    Wall JR; Good BF; Forbes IJ; Hetzel BS
    Clin Exp Immunol; 1973 Aug; 14(4):555-61. PubMed ID: 4201115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of Graves' ophthalmopathy without hyperthyroidism: long-acting thyroid stimulator (LATS) determination as laboratory adjunct.
    Gharib H; Mayberry WE
    Mayo Clin Proc; 1970 Jun; 45(6):444-9. PubMed ID: 4193249
    [No Abstract]   [Full Text] [Related]  

  • 15. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
    Hardisty CA; Hanford L; Munro DS
    Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of long-acting thyroid stimulator and of thyroid autoimmunity in the pathogenesis of euthyroid endocrine ophthalmopathy.
    Földes J; Takó J; Bános C; Gesztesi E
    Acta Med Acad Sci Hung; 1971; 28(2):171-9. PubMed ID: 5172524
    [No Abstract]   [Full Text] [Related]  

  • 17. [An antibody called LATS].
    Letonturier P; Tourneur R
    Nouv Presse Med; 1975 Jan; 4(3):177-9. PubMed ID: 1079340
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
    Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
    Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
    [No Abstract]   [Full Text] [Related]  

  • 19. The immunologic basis of Graves's disease.
    Volpé R
    N Engl J Med; 1972 Aug; 287(9):463-4. PubMed ID: 5068098
    [No Abstract]   [Full Text] [Related]  

  • 20. Changes in thyroid-stimulating immunoglobulins during antithyroid therapy.
    Fenzi G; Hashizume K; Roudebush CP; DeGroot LJ
    J Clin Endocrinol Metab; 1979 Apr; 48(4):572-6. PubMed ID: 581875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.